Intuitive Surgical stock steadies as Q2 2026 robotics growth drives recurring revenue
Published on 08/27/2026 at 07:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical, Inc. (US46120E6023) stock is holding a firm position in the US healthcare sector as recent data for the second quarter of 2026 highlight strong growth in robotic procedures and an expanding installed base of da Vinci and Ion systems as of August 26, 2026.
Per a recent sector overview dated August 26, 2026, Intuitive Surgical generated total revenue of $2.89 billion in the last reported quarter, reflecting year-over-year growth of 18.5% and demonstrating how higher procedure volumes are now translating directly into recurring instrument and service sales.
The same overview notes that earnings per share reached $2.80 in this latest quarter compared with $2.19 one year earlier, underscoring the operating leverage in the company’s robotics platform as utilization improves.
Q1 and Q2 2026 results show accelerating scale
While the most recent quarterly figures point to revenue of $2.89 billion and EPS of $2.80 for Intuitive Surgical, a detailed transcript of the first quarter 2026 earnings call provides important context on how the growth trajectory built through the first half of the year.
In the first quarter of 2026, management reported that total procedures grew 17%, including 16% growth in da Vinci procedures and 39% growth in Ion procedures, signaling broad-based adoption across both core and newer platforms.
Quarter one 2026 revenue increased 23% to $2.77 billion, with recurring revenue also higher by 23% to $2.4 billion, accounting for 86% of total revenue in that period and indicating that the majority of the business is now driven by ongoing utilization rather than one-time system sales.
The Q1 2026 call further highlighted that service revenue in the period rose 19% to $434 million, supported by a 12% increase in the da Vinci installed base and a 22% increase in the Ion installed base, reinforcing the installed-base growth that underpins future consumables and service demand.
Non-GAAP gross margin in Q1 2026 reached 67.8%, up from 66.4% in the first quarter of the prior year, demonstrating that scale and mix toward higher-margin da Vinci 5 systems were already improving profitability even before the latest quarter’s revenue acceleration.
Q2 2026 robotics metrics highlight global demand
A thematic robotics and physical AI analysis published August 26, 2026 points to Intuitive Surgical’s second quarter 2026 operational metrics as evidence of robust, global demand for minimally invasive robotic procedures.
In the second quarter of 2026, the company placed 468 da Vinci systems, up from 395 systems a year earlier, which represents a growth of 18.5% in placements and expanded the installed base 12% to 11,710 systems worldwide by the end of the quarter.
Over the same Q2 2026 period, procedure volume grew 15%, extending the utilization gains seen in the first quarter and reinforcing a pattern where higher system throughput feeds into recurring instruments, accessories, and service revenue.
Instruments and accessories revenue in Q2 2026 rose 18% to $1.73 billion, accounting for roughly 60% of Intuitive Surgical’s $2.89 billion total revenue in that quarter and underscoring how consumable usage has become the primary revenue driver.
Additional recent coverage focusing on surgical robotics notes that second quarter 2026 revenues for Intuitive Surgical increased 19%, slightly above the 18.5% growth cited for the latest quarter in other data, and reports that total procedures increased 16%, with recurring revenue reaching 85% of sales as the installed base approaches 13,000 da Vinci and Ion systems globally.
Within Q2 2026, international da Vinci procedures grew 20%, SP procedures rose 61%, and Ion procedures increased 36%, highlighting that growth is not confined to one region or platform and that markets such as India, Japan, and Europe provided incremental volume even amid continued pressure in China.
For the current quarter ahead after Q2 2026, consensus expectations compiled in late August 2026 indicate that Intuitive Surgical is forecast to post earnings of $2.61 per share, representing projected year-over-year growth of 8.8% and suggesting that analysts expect continued, though moderating, expansion following the strong first half.
Market performance and valuation snapshot
On August 25, 2026, Intuitive Surgical shares on Nasdaq closed at $371.67, giving the company a market capitalization of approximately $131.97 billion at that time and positioning it among the larger constituents of the US healthcare sector.
That same pricing snapshot shows that the 52-week trading range for Intuitive Surgical stock extended from $328.57 at the low end to $603.88 at the high end as of August 25, 2026, illustrating a wide band of volatility over the prior year as investors digested changing growth and valuation assumptions.
A parallel quote overview for the company’s secondary listing on Tradegate reported that the shares traded at 318.35 EUR on August 25, 2026, with that level consistent with a five-day decline of 0.66% and a year-to-date loss of 4.95%, providing European investors with a view of the stock’s recent underperformance on that venue despite longer-term strength.
Intraday market data from a widely used charting portal show that the current price of Intuitive Surgical stock is $545.39, representing a gain of 0.87% over the prior 24 hours as of the latest August 27, 2026 snapshot, which indicates that the shares have rebounded significantly from the late-August closing level referenced on Nasdaq.
Comparing the $545.39 quote with the prior 52-week high of $603.88 suggests that Intuitive Surgical stock is trading 9.7% below that peak as of the most recent data, leaving headroom relative to its historical high while still reflecting a substantial premium over the 52-week low.
The move from the $371.67 close on August 25, 2026 to the recent $545.39 level as of August 27, 2026 represents a sharp appreciation of 46.7% in a short window, showing how quickly sentiment around surgical robotics and high-quality recurring revenue names can shift when investors refocus on growth and margins.
Relative to the market capitalization of $131.97 billion at the $371.67 level, a sustained price near $545 would imply a market cap above $190 billion, which, while not yet confirmed in a specific figure in the available data, illustrates the scale at which Intuitive Surgical could trade if the higher quote consolidates.
Analyst expectations and earnings power
Late-August 2026 earnings commentary that covers multiple healthcare names indicates that Intuitive Surgical’s revenue of $2.89 billion in the most recently reported quarter has become a reference point for analysts tracking premium surgical robotics franchises.
In that context, EPS of $2.80 for the quarter compared with $2.19 in the same period the prior year represents growth of 27.9%, which is stronger than the underlying 18.5% revenue growth and points to improving margins and operating efficiency.
As of August 26, 2026, consensus expectations for Intuitive Surgical put earnings for the current quarter at $2.61 per share, up 8.8% versus the same quarter a year ago based on compiled estimates, reflecting a view that growth remains healthy but may decelerate somewhat from the very strong first-half trends.
The fact that consensus EPS estimates for the upcoming quarter remained unchanged over the last 30 days, according to that same overview, suggests a period of relative stability in analyst modeling, even as the share price has moved significantly in late August.
From an investor’s perspective, the mix of high recurring revenue, double-digit procedure growth, and expanding gross margin in Q1 2026, combined with strong revenue and EPS gains in Q2 2026, offers a clear quantitative picture of earnings power that depends heavily on utilization and system penetration rather than sporadic capital expenditure cycles.
The quantified comparisons across quarters also show how Intuitive Surgical’s growth is layered: Q1 2026 revenue up 23% to $2.77 billion versus Q2 2026 revenue of $2.89 billion up 18.5% year-over-year, Q1 gross margin improving 1.4 percentage points to 67.8%, and Q2 instruments and accessories revenue rising 18% to $1.73 billion to represent around 60% of total quarterly revenue.
Da Vinci systems underpin the business model
Intuitive Surgical’s da Vinci robotic platform sits at the center of its business model, providing surgeons with minimally invasive tools and driving recurring demand for instruments, accessories, and service.
As of the end of the second quarter 2026, the company’s installed base of da Vinci systems reached 11,710 units, up 12% from the prior year, which creates a wide foundation across hospitals and surgical centers for future procedure volumes and related consumable sales.
In Q1 2026, da Vinci procedures increased 16%, while in Q2 2026 overall procedure volume grew 15%, underscoring how usage per system is trending higher even as the installed base expands, a combination that supports both top-line growth and margin improvement.
The strong adoption of newer configurations such as da Vinci 5 and SP, along with Ion systems for lung procedures, feeds a flywheel effect where each system placement not only generates an initial sale but also years of follow-on instrument and service revenue, which already accounted for 86% of total revenue in Q1 2026 and 85% in Q2 2026 according to recent analyses.
For healthcare providers, the da Vinci platform’s value proposition is tied to clinical outcomes and efficiency, while for shareholders the key numbers are procedure growth, installed-base expansion, and the percentage of revenue that comes from recurring sources rather than cyclical capital purchases.
Closing view and current stock level
Intuitive Surgical stock is currently quoted at $545.39 as of the latest available August 27, 2026 trading snapshot on its primary Nasdaq listing, showing a recent gain of 0.87% over the prior 24 hours.
This level places the shares below their 52-week high of $603.88 but well above the 52-week low of $328.57 as reported for August 25, 2026, reflecting both the volatility typical for high-growth healthcare technology names and the market’s willingness to assign a premium valuation to Intuitive Surgical’s expanding, recurring-revenue-driven robotics franchise.
Fact box
Company: Intuitive Surgical, Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 27, 2026, latest intraday snapshot): $545.39 USD
Market cap: $131.97 billion (as of August 25, 2026)
Sector / Industry: Health care equipment and services
Index membership: S&P 500
